Federal Circuit Narrows “Factual Findings” Requiring Deference During Claim Construction
The Disposition: On remand from the Supreme Court, the Federal Circuit affirmed its earlier decision finding the claims of Teva’s Orange Book patent for Copaxone invalid as indefinite. See Teva Pharmaceuticals USA, Inc. et al. v. Sandoz, Inc. et al., No. 12-1567 (June 18, 2015). Case History. In its initial review, the Federal Circuit reversed…